Back
Science

Long-Term Data Suggests Advanced Follicular Lymphoma Patients Can Achieve Cure

Generated on: Last updated: 2 sources
View source

Follicular Lymphoma: A Paradigm Shift Towards Cure

A recent analysis of long-term data suggests that a subset of patients with advanced-stage follicular lymphoma, a condition historically considered incurable, may now be considered cured. The findings, published in JAMA Oncology, indicate a paradigm shift in the understanding and approach to this disease.

The S0016 Clinical Trial

The study analyzed 15-year follow-up data from the S0016 clinical trial, conducted by the SWOG Cancer Research Network and funded by the National Cancer Institute. This Phase 3 trial, which began in 2001, enrolled 531 patients with untreated advanced-stage CD20-positive follicular lymphoma.

Patients were randomized to receive either rituximab plus CHOP (R-CHOP) or CHOP followed by radioimmunotherapy (CHOP-RIT).

Key Findings from the Analysis

The analysis revealed several significant findings over the 15-year follow-up period:

  • Approximately 70% of patients remained alive 15 years after starting treatment.
  • Cure modeling estimated that 42% of treated patients were cured of the disease. Cure modeling accounts for background mortality rates to determine the fraction of patients no longer susceptible to disease-related death.
  • The rate of disease relapse significantly decreased over time, falling from 6.8% in the first 5 years to 0.6% between years 15 and 20.
  • No statistically significant difference in 15-year overall survival rates was observed between the two treatment arms (R-CHOP vs. CHOP-RIT).

Implications for Patient Care

Authors concluded that a substantial subset of patients receiving standard chemoimmunotherapy can achieve a functional cure, meaning no chance of lymphoma recurring during their expected lifespan.

Mazyar Shadman, MD, MPH, first author on the paper, noted that these results reinforce front-line chemoimmunotherapy as an important option for long-term disease control. The findings also suggest potential changes in patient counseling and the possibility of transitioning patients from indefinite oncology follow-up to primary care.